Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy

被引:205
作者
Trotman, RL
Williamson, JC
Shoemaker, DM
Salzer, WL
机构
[1] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Infect Dis Sect, Winston Salem, NC 27157 USA
[2] Univ Missouri, Hlth Sci Ctr, Dept Internal Med, Div Infect Dis, Columbia, MO USA
关键词
D O I
10.1086/444500
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Continuous renal replacement therapy (CRRT) is now commonly used as a means of support for critically ill patients with renal failure. No recent comprehensive guidelines exist that provide antibiotic dosing recommendations for adult patients receiving CRRT. Doses used in intermittent hemodialysis cannot be directly applied to these patients, and antibiotic pharmacokinetics are different than those in patients with normal renal function. We reviewed the literature for studies involving the following antibiotics frequently used to treat critically ill adult patients receiving CRRT: vancomycin, linezolid, daptomycin, meropenem, imipenem-cilastatin, nafcillin, ampicillin-sulbactam, piperacillin-tazobactam, ticarcillin-clavulanic acid, cefazolin, cefotaxime, ceftriaxone, ceftazidime, cefepime, aztreonam, ciprofloxacin, levofloxacin, moxifloxacin, clindamycin, colistin, amikacin, gentamicin, tobramycin, fluconazole, itraconazole, voriconazole, amphotericin B (deoxycholate and lipid formulations), and acyclovir. We used these data, as well as clinical experience, to make recommendations for antibiotic dosing in critically ill patients receiving CRRT.
引用
收藏
页码:1159 / 1166
页数:8
相关论文
共 61 条
[51]   Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration [J].
Tegeder, I ;
Neumann, F ;
Bremer, F ;
Brune, K ;
Lötsch, J ;
Geisslinger, G .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (01) :50-57
[52]   Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration [J].
Thalhammer, F ;
Schenk, P ;
Burgmann, H ;
El Menyawi, I ;
Hollenstein, UM ;
Rosenkranz, AR ;
Sunder-Plassmann, G ;
Breyer, S ;
Ratheiser, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2417-2420
[53]   ELIMINATION OF LIPOSOMAL AMPHOTERICIN BY HEMODIAFILTRATION [J].
TOMLIN, M ;
PRIESTLEY, GS .
INTENSIVE CARE MEDICINE, 1995, 21 (08) :699-700
[54]   Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients [J].
Traunmüller, F ;
Schenk, P ;
Mittermeyer, C ;
Thalhammer-Scherrer, R ;
Ratheiser, K ;
Thalhammer, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 (01) :129-134
[55]   Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients [J].
Traunmüller, F ;
Thalhammer-Scherrer, R ;
Locker, GJ ;
Losert, H ;
Schmid, R ;
Staudinger, T ;
Thalhammer, F .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 47 (02) :229-231
[56]   Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure [J].
Valtonen, M ;
Tiula, E ;
Backman, JT ;
Neuvonen, PJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (05) :701-704
[57]   Elimination of the piperacillin/tazobactam combination during continuous venovenous haemofiltration and haemodiafiltration in patients with acute renal failure [J].
Valtonen, M ;
Tiula, E ;
Takkunen, O ;
Backman, JT ;
Neuvonen, PJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 (06) :881-885
[58]   Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure [J].
Valtonen, M ;
Tiula, E ;
Neuvonen, PJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (05) :695-700
[59]   Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH) [J].
vanderWerf, TS ;
Mulder, POM ;
Zijlstra, JG ;
Uges, DRA ;
Stegeman, CA .
INTENSIVE CARE MEDICINE, 1997, 23 (08) :873-877
[60]   Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration [J].
Ververs, TFT ;
van Dijk, A ;
Vinks, SATMM ;
Blankestijn, PJ ;
Savelkoul, TJF ;
Meulenbelt, J ;
Boereboom, FTJ .
CRITICAL CARE MEDICINE, 2000, 28 (10) :3412-3416